Progression free survival poorly correlates with health-related quality of life in cancer trials

Originally Published By 2 Minute Medicine®. Reused on ONA with permission.
Share this content:

1. Progression free survival demonstrates poor-correlation with measures of health related quality of life (HRQoL) in oncology trials.

2. Current study demonstrate poor follow-up and reporting of HRQoL measures, likely introducing bias into published results.

Evidence Rating Level:3 (Average)

Study Rundown: Current stated goals for the American Society of Clinical Oncology include the focus on patient-centered outcomes in oncology clinical trials. Established themes on the values of patients include overall-survival (OS) and HRQoL. Trials evaluating OS require large study populations, long-term follow-up, high expense, and added complexity if cross-over is allowed. Evaluation of surrogate markers including progression-free survival (PFS) has become more common, with many medications being approved based on this outcome. How PFS correlates with patient-centered outcomes such as HRQoL is unclear. The current study sought to evaluate the relationship between reported HRQoL and PFS in oncology trials. The study demonstrated poor correlation between HRQoL and PFS, but with a noted high probability of bias from the HRQoL results and poor follow-up of HRQoL outcomes.

The current study highlights the need for further investigation into HRQoL outcomes as a primary endpoint of drug development in oncology. The strength of the study include the large number of included studies. The main limitations of the study stem from the poorly reported HRQoL outcomes in many published studies resulting in high degree of bias.

Click to read the study in JAMA Internal Medicine 

Relevant Reading: Clinical Trial Participation as Part of End-of-Life Cancer Care: Associations With Medical Care and Quality of Life Near Death

In-Depth [systematic review]: This study was a systematic review of randomized trials of patients with cancer evaluating chemotherapy from 2000 to 2016. The study excluded trials without PFS or HRQoL outcomes reported.

The study included 52 trials involving 38 randomized trials of chemotherapy agents for cancer. There was no strong association between PFS and global  HRQoL (slope of association 0.12, 95%CI, −0.27 to 0.52); physical HRQoL (−0.20, 95%CI, −0.62 to 0.23); or  emotional HRQoL (0.78, 95%CI, −0.05 to 1.60). There was a high risk of bias in84% of trials reporting at least 1 health-related quality of life measure.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Share this content:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs